Skip to content

Study · Animal study (in vivo) · 2014

9 results

Cerebrolysin reduces amyloid-β deposits, apoptosis and autophagy in the thalamus and improves functional recovery after cortical infarction.

Xing S, Zhang J, Dang C, Liu G, Zhang Y, Li J, Fan Y, Pei Z, Zeng J

Journal of the neurological sciences26 Nov 2013Cited by 42 (Europe PMC)

PMID24315581 (opens in a new tab)DOI10.1016/j.jns.2013.11.028 (opens in a new tab)PepBankPUB-24315581
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    After cerebral infarction, cerebrolysin improved sensory deficit compared with saline controls.

    In plain wordsIn animals with cerebral infarction, cerebrolysin improved sensory function compared with saline controls.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseSensory deficit
    Study

    n: not reported in source

    distal middle cerebral artery occlusion
    Comparator
    Saline control
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    5 ml/kg · intraperitoneal injection · 13 daysAs given in this study.

    Source sentences

    Summary
    The results showed that Cerebrolysin significantly improved sensory deficit compared to controls (p<0.05).
    2 context sentences
    Summary · context
    At 24h after distal middle cerebral artery occlusion (MCAO), Cerebrolysin (5 ml/kg) or saline as control was once daily administered for consecutive 13 days by intraperitoneal injection.
    Summary · context
    Sensory function and secondary thalamic damage were assessed with adhesive-removal test, Nissl staining and immunofluorescence at 14 days after MCAO.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    After cerebral infarction, cerebrolysin reduced thalamic amyloid-beta deposits compared with controls.

    In plain wordsIn animals with cerebral infarction, cerebrolysin reduced amyloid deposits compared with controls.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseAmyloid-beta deposits
    Study

    n: not reported in source

    distal middle cerebral artery occlusion
    Comparator
    Saline control
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    5 ml/kg · intraperitoneal injection · 13 daysAs given in this study.

    Source sentences

    Summary
    Aβ deposits and BACE1 were obviously reduced by Cerebrolysin, which was accompanied by decreases in neuronal loss and astroglial activation compared to controls (all p < 0.05).
    2 context sentences
    Summary · context
    At 24h after distal middle cerebral artery occlusion (MCAO), Cerebrolysin (5 ml/kg) or saline as control was once daily administered for consecutive 13 days by intraperitoneal injection.
    Summary · context
    Sensory function and secondary thalamic damage were assessed with adhesive-removal test, Nissl staining and immunofluorescence at 14 days after MCAO.
  3. 03AnimalAnimal study (in vivo)Mechanism

    After cerebral infarction, cerebrolysin reduced thalamic BACE1 compared with controls.

    In plain wordsIn animals with cerebral infarction, cerebrolysin reduced BACE1 compared with controls.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseBACE1
    Study

    n: not reported in source

    distal middle cerebral artery occlusion
    Comparator
    Saline control
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    5 ml/kg · intraperitoneal injection · 13 daysAs given in this study.

    Source sentences

    Summary
    Aβ deposits and BACE1 were obviously reduced by Cerebrolysin, which was accompanied by decreases in neuronal loss and astroglial activation compared to controls (all p < 0.05).
    2 context sentences
    Summary · context
    At 24h after distal middle cerebral artery occlusion (MCAO), Cerebrolysin (5 ml/kg) or saline as control was once daily administered for consecutive 13 days by intraperitoneal injection.
    Summary · context
    Sensory function and secondary thalamic damage were assessed with adhesive-removal test, Nissl staining and immunofluorescence at 14 days after MCAO.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    After cerebral infarction, cerebrolysin reduced thalamic neuronal loss compared with controls.

    In plain wordsIn animals with cerebral infarction, cerebrolysin reduced neuron loss compared with controls.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseNeuronal loss
    Study

    n: not reported in source

    distal middle cerebral artery occlusion
    Comparator
    Saline control
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    5 ml/kg · intraperitoneal injection · 13 daysAs given in this study.

    Source sentences

    Summary
    Aβ deposits and BACE1 were obviously reduced by Cerebrolysin, which was accompanied by decreases in neuronal loss and astroglial activation compared to controls (all p < 0.05).
    2 context sentences
    Summary · context
    At 24h after distal middle cerebral artery occlusion (MCAO), Cerebrolysin (5 ml/kg) or saline as control was once daily administered for consecutive 13 days by intraperitoneal injection.
    Summary · context
    Sensory function and secondary thalamic damage were assessed with adhesive-removal test, Nissl staining and immunofluorescence at 14 days after MCAO.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    After cerebral infarction, cerebrolysin reduced thalamic astroglial activation compared with controls.

    In plain wordsIn animals with cerebral infarction, cerebrolysin reduced astroglial activation compared with controls.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseAstroglial activation
    Study

    n: not reported in source

    distal middle cerebral artery occlusion
    Comparator
    Saline control
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    5 ml/kg · intraperitoneal injection · 13 daysAs given in this study.

    Source sentences

    Summary
    Aβ deposits and BACE1 were obviously reduced by Cerebrolysin, which was accompanied by decreases in neuronal loss and astroglial activation compared to controls (all p < 0.05).
    2 context sentences
    Summary · context
    At 24h after distal middle cerebral artery occlusion (MCAO), Cerebrolysin (5 ml/kg) or saline as control was once daily administered for consecutive 13 days by intraperitoneal injection.
    Summary · context
    Sensory function and secondary thalamic damage were assessed with adhesive-removal test, Nissl staining and immunofluorescence at 14 days after MCAO.
  6. 06AnimalAnimal study (in vivo)Mechanism

    After cerebral infarction, cerebrolysin inhibited cleaved caspase-3 in the ipsilateral thalamus compared with controls.

    In plain wordsIn animals with cerebral infarction, cerebrolysin reduced cleaved caspase-3 compared with controls.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseCleaved caspase-3
    Study

    n: not reported in source

    distal middle cerebral artery occlusion
    Comparator
    Saline control
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    5 ml/kg · intraperitoneal injection · 13 daysAs given in this study.

    Source sentences

    Summary
    Coincidently, Cerebrolysin markedly inhibited cleaved caspase-3, conversion of LC3-II, downregulation of Bcl-2 and upregulation of Bax in the ipsilateral thalamus compared to controls (all p<0.05).
    2 context sentences
    Summary · context
    At 24h after distal middle cerebral artery occlusion (MCAO), Cerebrolysin (5 ml/kg) or saline as control was once daily administered for consecutive 13 days by intraperitoneal injection.
    Summary · context
    Sensory function and secondary thalamic damage were assessed with adhesive-removal test, Nissl staining and immunofluorescence at 14 days after MCAO.
  7. 07AnimalAnimal study (in vivo)Mechanism

    After cerebral infarction, cerebrolysin inhibited LC3-II conversion in the ipsilateral thalamus compared with controls.

    In plain wordsIn animals with cerebral infarction, cerebrolysin reduced LC3-II conversion compared with controls.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseLC3-II conversion
    Study

    n: not reported in source

    distal middle cerebral artery occlusion
    Comparator
    Saline control
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    5 ml/kg · intraperitoneal injection · 13 daysAs given in this study.

    Source sentences

    Summary
    Coincidently, Cerebrolysin markedly inhibited cleaved caspase-3, conversion of LC3-II, downregulation of Bcl-2 and upregulation of Bax in the ipsilateral thalamus compared to controls (all p<0.05).
    2 context sentences
    Summary · context
    At 24h after distal middle cerebral artery occlusion (MCAO), Cerebrolysin (5 ml/kg) or saline as control was once daily administered for consecutive 13 days by intraperitoneal injection.
    Summary · context
    Sensory function and secondary thalamic damage were assessed with adhesive-removal test, Nissl staining and immunofluorescence at 14 days after MCAO.
  8. 08AnimalAnimal study (in vivo)Mechanism

    After cerebral infarction, cerebrolysin inhibited Bcl-2 downregulation in the ipsilateral thalamus compared with controls.

    In plain wordsIn animals with cerebral infarction, cerebrolysin limited the decrease in Bcl-2 compared with controls.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseBcl-2 downregulation
    Study

    n: not reported in source

    distal middle cerebral artery occlusion
    Comparator
    Saline control
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    5 ml/kg · intraperitoneal injection · 13 daysAs given in this study.

    Source sentences

    Summary
    Coincidently, Cerebrolysin markedly inhibited cleaved caspase-3, conversion of LC3-II, downregulation of Bcl-2 and upregulation of Bax in the ipsilateral thalamus compared to controls (all p<0.05).
    2 context sentences
    Summary · context
    At 24h after distal middle cerebral artery occlusion (MCAO), Cerebrolysin (5 ml/kg) or saline as control was once daily administered for consecutive 13 days by intraperitoneal injection.
    Summary · context
    Sensory function and secondary thalamic damage were assessed with adhesive-removal test, Nissl staining and immunofluorescence at 14 days after MCAO.
  9. 09AnimalAnimal study (in vivo)Mechanism

    After cerebral infarction, cerebrolysin inhibited Bax upregulation in the ipsilateral thalamus compared with controls.

    In plain wordsIn animals with cerebral infarction, cerebrolysin limited the increase in Bax compared with controls.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseBax upregulation
    Study

    n: not reported in source

    distal middle cerebral artery occlusion
    Comparator
    Saline control
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    5 ml/kg · intraperitoneal injection · 13 daysAs given in this study.

    Source sentences

    Summary
    Coincidently, Cerebrolysin markedly inhibited cleaved caspase-3, conversion of LC3-II, downregulation of Bcl-2 and upregulation of Bax in the ipsilateral thalamus compared to controls (all p<0.05).
    2 context sentences
    Summary · context
    At 24h after distal middle cerebral artery occlusion (MCAO), Cerebrolysin (5 ml/kg) or saline as control was once daily administered for consecutive 13 days by intraperitoneal injection.
    Summary · context
    Sensory function and secondary thalamic damage were assessed with adhesive-removal test, Nissl staining and immunofluorescence at 14 days after MCAO.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.